Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Syngene में भारी गिरावट देखने को मिल रही है, ऐसे में जानें कितना और नीचे जा सकता है Stock, देखें वीडियो.

#CNBCAwaazLive #Syngene #SyngeneShareNews  #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive



CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Syngene Share News: जानें नीचे किन Levels तक जा सकता है Stock? | Kamai Ka Adda | CNBC Awaaz

ICICI Direct is bullish on Syngene International has recommended buy rating on the stock with a target price of Rs 730 in its research report dated April 29, 2022.

Buy Syngene International; target of Rs 730: ICICI Direct

Syngene's Q4 net profit skid 8% even as revenue jumped 15% on a sequential basis.

MD & CEO Jonathan Hunt talks about the quarter gone by and growth outlook for next fiscal. #BQLive #Q4WithBQ

--------------------------------------------------------------------------------------------------------------------
For more videos subscribe to our channel: http://bit.ly/32JXa74
Visit BloombergQuint for more news: https://www.bloombergquint.com
Don't enter the stock market unaware. Read all Research Reports here: https://bit.ly/2XJDekQ

For the latest business news and analysis
Subscribe to #BQBlue: http://bit.ly/2JgWQpe
Subscribe to our Newsletters here: https://bit.ly/3EPskgI
Subscribe to our Telegram channel: https://t.me/bloombergquint

Follow BloombergQuint here
Twitter: http://bit.ly/2WS718f
Facebook: http://bit.ly/2leyPGj
LinkedIn: http://bit.ly/2mOwl21
Instagram: https://bit.ly/31Twh5t

Q4 Review: Analysing Syngene's Report Card

Syngene Intl Consolidated March 2022 Net Sales at Rs 758.10 crore, up 15.11% Y-o-Y

The company had reported a PAT of Rs 138 crore in the January-March period of 2020-21

Syngene’s Q4 PAT up 7% to Rs 148 cr; revenue rises 15% to Rs 758 cr

Syngene International consolidated net profit declines 7.97% in the March 2022 quarter

Syngene International’s consolidated net profit fell 7.97% to Rs 147.80 crore on a 15.10% rise in revenue from operations to Rs 758.10 crore in Q4 FY22 over Q4 FY21.

Syngene International Q4 FY22 PAT slips 8% YoY to Rs 148 cr

Based on the open interest future percentage, a long unwinding was seen in 112 stocks including Jubilant Foodworks, Pfizer, Tata Power, Alkem Laboratories, and Syngene International.

Trade setup for today: Top 15 things to know before the opening bell

The rating on the short-term bank facilities has been reaffirmed at ‘CRISIL A1+’.

CRISIL places AA+ rating on the long-term bank facilities of Syngene on ‘Watch with Developing Implications’

Buzzing stocks: Reliance Ind, automobile cos, L&T Finance Holdings, Vipul Organics, Prestige Estates, Bharat Forge, Syngene International, Lupin, Lemon Tree, Route Mobile, Quint Digital, Infibeam Avenues, IIFL Asset

Stocks that will see action on March 2

ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 710 in its research report dated January 21, 2022.

Buy Syngene International; Target Of Rs 710: ICICI Direct

Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.

Syngene International Ltd

Syngene International Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

Syngene Share News: जानें नीचे किन Levels तक जा सकता है Stock? | Kamai Ka Adda | CNBC Awaaz

Buy Syngene International; target of Rs 730: ICICI Direct

News Video

Q4 Review: Analysing Syngene's Report Card

Syngene Intl Consolidated March 2022 Net Sales at Rs 758.10 crore, up 15.11% Y-o-Y

Syngene’s Q4 PAT up 7% to Rs 148 cr; revenue rises 15% to Rs 758 cr

Syngene International consolidated net profit declines 7.97% in the March 2022 quarter

Syngene International Q4 FY22 PAT slips 8% YoY to Rs 148 cr

Syngene International Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

Syngene Share News: जानें नीचे किन Levels तक जा सकता है Stock? | Kamai Ka Adda | CNBC Awaaz

Buy Syngene International; target of Rs 730: ICICI Direct

News Video

Q4 Review: Analysing Syngene's Report Card

Syngene Intl Consolidated March 2022 Net Sales at Rs 758.10 crore, up 15.11% Y-o-Y

Syngene’s Q4 PAT up 7% to Rs 148 cr; revenue rises 15% to Rs 758 cr

Syngene International consolidated net profit declines 7.97% in the March 2022 quarter

Syngene International Q4 FY22 PAT slips 8% YoY to Rs 148 cr

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock